Background: Recently, Mutations in discoidin domain receptor 2 (DDR2) gene were recently identified as promising molecular targets in non-small-cell lung cancer. While the genetic spectrum of DDR2 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring DDR2 mutations. Method: A total of 283 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of DDR2 mutation and other genes were detected by next generation sequencing. Result: DDR2 gene mutation rate was 3.18% (9/283) in non-small cell lung cancer, including S311N (3 patients), E44K (1 patient), R709Q (1 patient), T564I (1 patient), R742Q (1 patient), G206* (1 patient) and M117I (1 patient), and median overall survival (OS) for these patients was 20.0 months. Among them, all patients were DDR2 gene with co-occurring mutation. Briefly, patients with (n¼6) or without (n¼3) cooccurring EGFR mutations had a median OS of 20.0 months and 9.0 months respectively (P¼0.29); patients with (n¼4) or without (n¼5) co-occurring TP53 mutations had a median OS of 17.0 months and 21.5 months respectively (P¼0.63); patients with (n¼2) or without (n¼7) co-occurring KRAS mutations had a median OS of 13.5 months and 20.0 months respectively (P¼0.82); patients with (n¼2) or without (n¼7) co-occurring PTPRD mutations had a median OS of 15.0 months and 20.0 months respectively (P¼0.96). Conclusion: DDR2 mutations were observed in 3.18 % of cases of NSCLC. DDR2-mutated NSCLC can exhibit other driver gene alterations. No clinical characteristics were significantly associated with DDR2 mutation.
Background: Recently, Mutations in discoidin domain receptor 2 (DDR2) gene were recently identified as promising molecular targets in non-small-cell lung cancer. While the genetic spectrum of DDR2 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring DDR2 mutations. Method: A total of 283 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of DDR2 mutation and other genes were detected by next generation sequencing. Result: DDR2 gene mutation rate was 3.18% (9/283) in non-small cell lung cancer, including S311N (3 patients), E44K (1 patient), R709Q (1 patient), T564I (1 patient), R742Q (1 patient), G206* (1 patient) and M117I (1 patient), and median overall survival (OS) for these patients was 20.0 months. Among them, all patients were DDR2 gene with co-occurring mutation. Briefly, patients with (n¼6) or without (n¼3) cooccurring EGFR mutations had a median OS of 20.0 months and 9.0 months respectively (P¼0.29); patients with (n¼4) or without (n¼5) co-occurring TP53 mutations had a median OS of 17.0 months and 21.5 months respectively (P¼0.63); patients with (n¼2) or without (n¼7) co-occurring KRAS mutations had a median OS of 13.5 months and 20.0 months respectively (P¼0.82); patients with (n¼2) or without (n¼7) co-occurring PTPRD mutations had a median OS of 15.0 months and 20.0 months respectively (P¼0.96). Background: The role of BRCA2 gene somatic mutations are mainly to maintain genome integrity in response to DNA damage through different mechanisms. Deregulation of BRCA2 is associated with the development of tumor and altered sensitivity to chemotherapeutic agents, but the genetic variability of BRCA2 somatic mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring BRCA2 somatic mutations. Method: A total of 362 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of BRCA2 somatic mutation and other genes were detected by next generation sequencing. Result: BRCA2 gene somatic mutation rate was 4.97% (18/362) in non-small cell lung cancer, including S547P (2 patients), G1433W (2 patients), I488V (1 patient), C315S (1 patient), T2007S (1 patient), I1929V (1 patient), H3117Y (1 patient), G1370V (1 patient), T768S (1 patient), E2260Q (1 patient), R2087K (1 patient), E3167Q (1 patient), S163T (1 patient), T152I (1 patient), E2275Q (1 patient) and S163T (1 patient) , and median overall survival (OS) for these patients was 18.0 months. Among them, all patients were BRCA2 gene with co-occurring somatic mutation. Briefly, patients with (n¼3) or without (n¼15) co-occurring EGFR mutations had a median OS of 21.0 months and 18.0 months respectively (P¼0.22); patients with (n¼11) or without (n¼7) cooccurring TP53 mutations had a median OS of 7.5 months and 18.0 months respectively (P¼0.15); patients with (n¼2) or without (n¼16) co-occurring HER2 mutations had a median OS of 11.0 months and 20.0 months respectively (P¼0.24). Background: Recently, CTNNB1, encoding beta-catenin, is a wellknown tumor-related gene in the wnt signaling pathway. While the genetic variability of CTNNB1 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring CTNNB1 mutations. Method: A total of 677 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of CTNNB1 mutation and other genes were detected by next generation sequencing. Result: CTNNB1 gene mutation rate was 1.92% (13/677) in non-small cell lung cancer, including S33F (4 patients), S33C (1 patient), D32H (1 patient), G34R (1 patient), G34V (1 patient), G34del (1 patient), D11G (1 patient), S45P (1 patient), S45F (1 patient) and S45del plus S33Y (1 patient), and median overall survival (OS) for these patients was 12.0 months. Among them, all patients were CTNNB1 gene with co-occurring mutations. Briefly, patients with (n¼7) or without (n¼6) co-occurring EGFR mutations had a median OS of 25.8 months and 8.5 months respectively (P¼0.18); patients with (n¼10) or without (n¼3) co-occurring TP53 mutations had a median OS of 10.0 months and 17.5 months respectively (P¼0.35); patients with (n¼2) or without (n¼11) co-occurring BRAF mutations had a median OS of 7.5 months and 13.0 months respectively (P¼0.14); patients with (n¼2) or without (n¼11) co-occurring ATM mutations had a median OS of 17.5 months and 11.0 months respectively (P¼0.53). Conclusion: Accompanied gene has not well been connected with CTNNB1 gene mutations. Our finding expands the mutant spectrum of CTNNB1 gene and adds new understanding of the phenotype. Keywords: CTNNB1 mutation, Non-small-cell lung cancer, Prognosis
